Eledon Pharmaceuticals, Inc. (ELDN) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Eledon Pharmaceuticals, Inc. (ELDN) closed at USD 2.25 on 2026-10-14, a change of -43.5 % over the past year, with a market capitalization of USD 184.46M.
Eledon Pharmaceuticals, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 2.25 |
| 2026-10-13 | 2.34 |
| 2026-10-12 | 2.44 |
| 2026-10-09 | 2.48 |
| 2026-10-08 | 2.42 |
| 2026-10-07 | 2.42 |
| 2026-10-06 | 2.45 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Eledon Pharmaceuticals, Inc. key figures
- Previous close
- USD 2.25 (2026-10-14)
- 1-year change
- -43.5 %
- Market cap
- USD 184.46M
- Enterprise value
- USD 96.17M
- P/E ratio (trailing)
- -2.61
- P/E ratio (forward)
- -2.95
- EPS (trailing)
- -0.87
- EPS (forward)
- -0.77
- PEG ratio
- n/a
- Price to book
- 2.55
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 8.20
- Employees
- 33
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Eledon Pharmaceuticals, Inc. and compare it with other stocks.
Analyze ELDNAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Eledon Pharmaceuticals, Inc. shares.